Should You Be Worried About the Return of Big Pharma Deals?

Plenty of big pharmaceutical companies started 2018 with piles of cash burning holes in their pockets. The pace of acquisitions and large licensing deals cooled off after hitting a crescendo in late April, but plenty of the industry's well-heeled members are still eager to invest.